The head of JNJ Innovation for the east of North America talks about recent deals and JNJ’s support of science at its earliest stages.

William Blair’s Andy Hsieh discusses recent data from CymaBay, and comments on Madrigal, Viking, Exelixis, POINT, Fusion, and Icosavax.

Uli Stilz talks about the collaborating on science that might slow or reverse the progression of cardiometabolic diseases.

March Biosciences’ CEO Sarah Hein on the infrastructure available in Houston for biotech startups, and the science behind her CD5 CAR-T.

Michael Torres describes his work in Texas, co-founding ReCode, helping entrepreneurs in Houston, and founding a next-gen ADC company.

Ann Tanabe describes the institutions, facilities, funding, and people that are coming together to make Houston a competitive biotech town.

Rachel Layman and Clinton Yam talk about recent ADCs, new ways of targeting the estrogen receptor, and next-gen ADCs.

Jeff Jones describes the science behind radiopharmaceuticals and how both new targets and better isotopes are making them more effective.

Funda Meric-Bernstam describes how ADCs have improved over recent years and lists some of her favorite targets and indications.

He describes how PARP inhibitors were initial successes and where the field is going now beyond PARP with new targets.

Tyler Van Buren discusses recent news from Acelyrin and Rocket Pharma, and comments on Moderna, BridgeBio, Iovance, and Allogene.

Ferdinandos Skoulidis describes improvements being made to G12C inhibitors and the theoretical potential for pan-RAS inhibitors.

Ferran Prat describes what advantages MD Anderson offers to drug developers running trials, what makes a good partner, and areas of science

Ross Barrett describes how the Cancer Focus Fund provides financing, advice, and help with getting into the clinic at MD Anderson.

Dr. Heymach discusses KRAS, refined TKI matching, antibody-drug conjugates, cell therapies, and cancer vaccines.

Leslie Williams explains how harnessing tRNA might be used for nonsense mutation diseases and for marking unwanted proteins for destruction.

Brian Gallagher describes what it is like raising venture funds in biotech today and also offers areas of science that he is focused on.

Brian Skorney discusses this week’s data from Neurocrine Biosciences and Crinetics, and comments on Amgen, Regeneron, and Arbutus.

Dennis Purcell talks about the biotech downturn, what areas of science interest him going forward, and memories of Hambrecht & Quist.

Dr. Frost describes the elements needed for a city to spark biotech innovation and the progress that Miami has been making.